Clinical Trial

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult patients. The safety of this drug combination will also be studied.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-04-21; most recent amendment 2026-05-18.
Trial Details
NCT Number NCT07551583
Lead Sponsor M.D. Anderson Cancer Center
Conditions Hodgkin Lymphoma
Enrollment 15 participants
Start Date 2026-10-01
Primary Completion 2030-12-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30